![]() Analyzing AIRR-seq data can prove challenging even with high-quality sequencing, in part due to the many steps involved and the need to parameterize each step. Recent advancements in the technology include sequencing at the single-cell level and in parallel with gene expression, which allows the introduction of multi-omics approaches to understand in detail the adaptive immune response. Since the method was first introduced in 2009, AIRR sequencing (AIRR-Seq) has been applied to survey the immune state of individuals, identify antigen-specific or immune-state-associated signatures of immune responses, study the development of the antibody immune response, and guide the development of vaccines and antibody therapies. The Company was founded in 2010 and has its headquarters in San Carlos, California.High-throughput sequencing of adaptive immune receptor repertoires (AIRR, i.e., IG and TR) has revolutionized the ability to carry out large-scale experiments to study the adaptive immune response. "Our investment will help Atreca commercialize this disruptive technology and rapidly identify new medicines to address significant patient need.”Ītreca, Inc., is a privately held biopharmaceutical company with an immune repertoire capture technology that revolutionizes the discovery and development of a wide range of products. “Atreca is an early-stage technology company with great potential," said Douglas Crawford, Ph.D., Managing Partner, Mission Bay Capital, and Associate Director of the California Institute for Quantitative Biosciences (QB3). and members of the Atreca management team Paulette Dillon, Daniel Emerling, Ph.D., Wayne Volkmuth, Ph.D., and Jonathan Woo, Ph.D.Ītreca has received initial funding from investors including Mission Bay Capital, whose team has deep collective experience investing in and building companies. (also an inventor), and Yann Chong Tan, Ph.D., (also an inventor) Guy Cavet, Ph.D. Other co-founders of Atreca include Stanford researchers Robert Axtell, Ph.D., Jeremy Sokolove, M.D. “This is a game-changing technology that will bring us closer to more effective medicines and vaccines.” Zimmermann Professor of Neurology and Neurological Sciences and Pediatrics at Stanford University, and a co-founder of Atreca. "What impresses me about this technology is its extremely rapid throughput and comprehensive output," said Lawrence Steinman, M.D., the George A. The technology is therefore a highly prolific engine for the discovery and development of therapeutic antibodies, vaccines, diagnostics, and research reagents.” “Immune repertoire capture, which leverages next-generation sequencing, identifies new antibodies that have utility themselves and that define the targets of functional immune responses. “It has been an amazing journey,” said Dr. Robinson, M.D., Ph.D., Associate Professor of Medicine in the Division of Immunology and Rheumatology at Stanford University. The immune repertoire capture technology was developed in the laboratories of William H. “Atreca will apply these capabilities across a broad range of applications.” Serafini, Ph.D., chief executive officer, chief scientific officer, and co-founder of Atreca, Inc. “This unique approach rapidly identifies the repertoire of functional antibodies generated in an effective immune response, which until now has been an intractable challenge,” said Tito A. SAN CARLOS, CA, USA I AugI Atreca, Inc., today announced that Stanford University has granted the company an exclusive license to transformational technology for harnessing the power of the immune response to generate a wide range of medical products. Proprietary approach will accelerate the discovery and development of novel therapeutic antibodies and vaccines.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |